Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Anemia in Chronic Kidney Disease (Renal Anemia) Overview | 10 | 1 |
| Therapeutics Development | 11 | 1 |
| Pipeline Products for Anemia in Chronic Kidney Disease (Renal Anemia) Overview | 11 | 1 |
| Anemia in Chronic Kidney Disease (Renal Anemia) Therapeutics under Development by Companies | 12 | 3 |
| Anemia in Chronic Kidney Disease (Renal Anemia) Pipeline Products Glance | 15 | 4 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Anemia in Chronic Kidney Disease (Renal Anemia) Products under Development by Companies | 19 | 2 |
| Anemia in Chronic Kidney Disease (Renal Anemia) Companies Involved in Therapeutics Development | 21 | 27 |
| 3SBio Inc. | 21 | 1 |
| Acceleron Pharma, Inc. | 22 | 1 |
| Akebia Therapeutics, Inc. | 23 | 1 |
| Amgen Inc. | 24 | 1 |
| Bayer AG | 25 | 1 |
| BIOCAD | 26 | 1 |
| CCM Duopharma Biotech Bhd. | 27 | 1 |
| Chong Kun Dang Pharmaceutical Corp. | 28 | 1 |
| CJ HealthCare Corp. | 29 | 1 |
| Daiichi Sankyo Company, Limited | 30 | 1 |
| Dr. Reddy's Laboratories Limited | 31 | 1 |
| Eli Lilly and Company | 32 | 1 |
| FibroGen, Inc. | 33 | 1 |
| GlaxoSmithKline Plc | 34 | 1 |
| Intas Pharmaceuticals Ltd. | 35 | 1 |
| Japan Tobacco Inc. | 36 | 1 |
| JCR Pharmaceuticals Co., Ltd. | 37 | 1 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | 38 | 1 |
| LG Life Science LTD. | 39 | 1 |
| Medgenics, Inc. | 40 | 1 |
| Myungmoon pharmaceutical Co., Ltd. | 41 | 1 |
| Panacea Biotec Limited | 42 | 1 |
| Pfizer Inc. | 43 | 1 |
| PharmaEssentia Corporation | 44 | 1 |
| Pieris Pharmaceuticals, Inc. | 45 | 1 |
| Sandoz International GmbH | 46 | 1 |
| Zydus Cadila Healthcare Limited | 47 | 1 |
| Anemia in Chronic Kidney Disease (Renal Anemia) Therapeutics Assessment | 48 | 9 |
| Assessment by Monotherapy Products | 48 | 1 |
| Assessment by Target | 49 | 2 |
| Assessment by Mechanism of Action | 51 | 2 |
| Assessment by Route of Administration | 53 | 2 |
| Assessment by Molecule Type | 55 | 2 |
| Drug Profiles | 57 | 59 |
| daprodustat Drug Profile | 57 | 2 |
| darbepoetin alfa Drug Profile | 59 | 3 |
| darbepoetin alfa Drug Profile | 62 | 1 |
| darbepoetin alfa Drug Profile | 63 | 1 |
| darbepoetin alfa Drug Profile | 64 | 1 |
| darbepoetin alfa Drug Profile | 65 | 1 |
| darbepoetin alfa Drug Profile | 66 | 1 |
| darbepoetin alfa Drug Profile | 67 | 1 |
| darbepoetin alfa Drug Profile | 68 | 1 |
| darbepoetin alfa Drug Profile | 69 | 1 |
| DS-1093 Drug Profile | 70 | 1 |
| EPO-018B Drug Profile | 71 | 1 |
| epoetin alfa Drug Profile | 72 | 2 |
| epoetin alfa Drug Profile | 74 | 1 |
| epoetin zeta Drug Profile | 75 | 3 |
| FG-2216 Drug Profile | 78 | 2 |
| JTZ-951 Drug Profile | 80 | 1 |
| LBDE Drug Profile | 81 | 1 |
| LY-3113593 Drug Profile | 82 | 1 |
| MDGN-201 Drug Profile | 83 | 2 |
| MMP-0101 Drug Profile | 85 | 1 |
| molidustat Drug Profile | 86 | 2 |
| P-1116 Drug Profile | 88 | 1 |
| PEG-EPO Drug Profile | 89 | 1 |
| Peg-EPO Drug Profile | 90 | 1 |
| PEG-EPO Drug Profile | 91 | 1 |
| PRS-080 Drug Profile | 92 | 3 |
| Recombinant Protein for Renal Anemia Drug Profile | 95 | 1 |
| roxadustat Drug Profile | 96 | 7 |
| Small Molecule to Inhibit HIF-PH for Renal Anemia Drug Profile | 103 | 1 |
| sotatercept Drug Profile | 104 | 5 |
| SSS-06 Drug Profile | 109 | 1 |
| vadadustat Drug Profile | 110 | 6 |
| Anemia in Chronic Kidney Disease (Renal Anemia) Dormant Projects | 116 | 1 |
| Anemia in Chronic Kidney Disease (Renal Anemia) Discontinued Products | 117 | 1 |
| Anemia in Chronic Kidney Disease (Renal Anemia) Product Development Milestones | 118 | 12 |
| Featured News &Press Releases | 118 | 1 |
| May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction | 118 | 1 |
| May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat | 118 | 1 |
| Apr 26, 2016: Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings | 119 | 1 |
| Apr 08, 2016: Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's nephrology indication | 119 | 1 |
| Mar 09, 2016: Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat | 120 | 1 |
| Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease | 120 | 2 |
| Jan 04, 2016: Akebia Initiates Phase 3 PRO2TECT Program | 122 | 1 |
| Oct 28, 2015: Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting | 123 | 2 |
| Aug 12, 2015: Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active Hif-Phi Roxadustat (Fg-4592) Shows Improved Hemoglobin Levels In Non-Dialysis Ckd Subjects With Anemia | 125 | 1 |
| Jul 15, 2015: Medgenics Announces First Patient Enrolled in U.S.-Based Phase 2 Clinical Trial of TARGT-EPO for Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis | 125 | 1 |
| May 26, 2015: Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual Congress | 126 | 1 |
| Mar 16, 2015: Akebia Announces Presentation of Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia at WCN | 126 | 2 |
| Mar 11, 2015: Bayer to Present Latest Clinical Data On Molidustat | 128 | 1 |
| Mar 10, 2015: Akebia Announces Completion of Enrollment in Phase 2 Trial of AKB-6548 in Dialysis Patients with Anemia Related to Chronic Kidney Disease | 128 | 1 |
| Oct 15, 2014: Medgenics Reports Positive Initial Clinical Data From Clinical Study Of MDGN-201 | 129 | 1 |
| Appendix | 130 | 2 |
| Methodology | 130 | 1 |
| Coverage | 130 | 1 |
| Secondary Research | 130 | 1 |
| Primary Research | 130 | 1 |
| Expert Panel Validation | 130 | 1 |
| Contact Us | 130 | 1 |
| Disclaimer | 131 | 1 |